Bavencio (Avelumab) Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Bavencio (avelumab) is a medication used in the treatment of certain cancers. It contains avelumab as the active ingredient, an immunotherapy agent that works by enabling the body's immune system to better recognize and attack cancer cells.

The main indications for Bavencio (avelumab) include Merkel cell carcinoma, non-small cell lung cancer (NSCLC), urothelial carcinoma, and gastric cancer. Merkel cell carcinoma (MCC) is a rare and aggressive type of skin cancer that originates in Merkel cells located in the outermost layer of the skin, known as the epidermis. The medication is administered through routes such as intravenous and subcutaneous injection and is used by end users including hospitals, clinics, and cancer research institutes.

Tariffs have impacted the bavencio market by increasing costs for monoclonal antibody production inputs, formulation materials, and temperature-controlled logistics. These impacts are strongest in regions dependent on imported immunotherapies, including asia pacific and emerging markets. Hospital procurement and oncology clinic budgets face higher acquisition costs. On the positive side, tariffs are encouraging localized immunotherapy manufacturing investments. This strengthens regional supply security and supports long-term market expansion.

The bavencio (avelumab) market research report is one of a series of new reports from The Business Research Company that provides bavencio (avelumab) market statistics, including bavencio (avelumab) industry global market size, regional shares, competitors with a bavencio (avelumab) market share, detailed bavencio (avelumab) market segments, market trends and opportunities, and any further data you may need to thrive in the bavencio (avelumab) industry. This bavencio (avelumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bavencio (avelumab) market size has grown rapidly in recent years. It will grow from $0.54 million in 2025 to $0.63 million in 2026 at a compound annual growth rate (CAGR) of 16.8%. The growth in the historic period can be attributed to clinical success of immuno-oncology drugs, approval in merkel cell carcinoma, rising cancer immunotherapy investment, improved survival outcomes, regulatory support for pd-l1 inhibitors.

The bavencio (avelumab) market size is expected to see rapid growth in the next few years. It will grow to $1.17 million in 2030 at a compound annual growth rate (CAGR) of 16.5%. The growth in the forecast period can be attributed to expansion into new tumor indications, increasing global immunotherapy adoption, growth in oncology clinical trials, improved biomarker driven treatment selection, rising healthcare oncology spending. Major trends in the forecast period include growing adoption of immune checkpoint inhibitors, expansion of pd-l1 targeted therapies, rising use of immunotherapy in solid tumors, combination use with chemotherapy and targeted drugs, increased focus on rare cancer indications.

The increasing prevalence of cancer is expected to drive the growth of the Bavencio (avelumab) market going forward. Cancer comprises a group of diseases marked by the uncontrolled growth and spread of abnormal cells within the body. The rise in cancer prevalence is attributed to factors such as unhealthy lifestyle choices, including poor diet and physical inactivity, greater exposure to environmental pollutants, and improvements in diagnostic and screening technologies. Bavencio (avelumab) supports cancer treatment by acting as an immune checkpoint inhibitor that enhances the body's natural immune response, enabling immune cells to better recognize and destroy cancer cells, while improving survival outcomes and quality of life for patients. For instance, in January 2023, according to the American Cancer Society, the number of new cancer cases in the United States reached 1,958,310 in 2023, with 609,820 cancer-related deaths reported. Therefore, the rising prevalence of cancer is driving the growth of the Bavencio (avelumab) market.

A key trend in the Bavencio (avelumab) market is the adoption of strategic partnerships to strengthen technology integration and expand market reach. Strategic partnerships involve collaborative agreements in which organizations pool resources, expertise, and capabilities to achieve shared objectives. For instance, in May 2025, Aulos Bioscience partnered with Merck KGaA in a clinical trial collaboration to evaluate a combination therapy of AU-007, an interleukin-2 (IL-2) therapeutic, with Bavencio (avelumab) and low-dose aldesleukin. The Phase 2 trial is designed to assess the potential of this combination in treating solid tumors. Bavencio's anti-PD-L1 mechanism, together with AU-007's immune-enhancing properties, has shown promising tumor-eradicating potential in preclinical studies.

In March 2023, Merck KGaA acquired exclusive worldwide rights to BAVENCIO (avelumab) from Pfizer Inc. for an undisclosed amount following the termination of their alliance agreement. This move aligns with Merck KGaA's strategy to strengthen its oncology portfolio and underscores its long-term commitment to BAVENCIO as an important treatment option for cancers such as metastatic Merkel cell carcinoma and advanced renal cell carcinoma. Pfizer Inc. is a US-based pharmaceutical manufacturing company involved in the production of BAVENCIO (avelumab).

Major companies operating in the bavencio (avelumab) market are Merck & Co. Inc., Pfizer Inc

North America was the largest region in the bavencio(avelumab) market in 2025. The regions covered in the bavencio (avelumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the bavencio (avelumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The bavencio (avelumab) market consists of sales of monotherapy and combination therapy. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bavencio (Avelumab) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses bavencio (avelumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bavencio (avelumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The bavencio (avelumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Indication: Merkel Cell Carcinoma; Non Small Cell Lung Cancer (NSCLC); Urothelial Carcinoma; Gastric Cancer
• 2) By Route of Administration: Intravenous; Subcutaneous
• 3) By End User: Hospitals; Clinics; Cancer Research Institutes
• Companies Mentioned: Merck & Co. Inc.; Pfizer Inc
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.